- Advertisement -
- Advertisement -
- Advertisement -

Find a job

Subscribe for free

All things Pharma

Roche collaborates with Lilly to enhance early diagnosis of Alzheimer’s disease

Roche has entered into a collaboration with Eli Lilly and Company to support the development of Roche’s Elecsys® Amyloid Plasma Panel (EAPP). The EAPP is an innovative blood test that aims to facilitate the earlier diagnosis of Alzheimer’s disease. Once approved, it could help healthcare professionals to streamline the journey to diagnosis for more patients.

Today, barriers to early and accurate diagnosis of Alzheimer’s exist across the globe with up to 75% of people living with the symptoms of Alzheimer’s, but without a diagnosis. Those who have received a diagnosis waited, on average, 2.8 years after symptom onset1. To address the growing strain that Alzheimer’s is putting on healthcare systems, it will be essential to make a person’s journey to diagnosis faster and more accessible. This will ultimately enable access to appropriate new therapies as they become available.

This collaboration is aligned to both Roche and Lilly’s shared objective to support patients by improving the journey to a timely and accurate diagnosis and treatment. If approved, the EAPP test would be an additional tool to identify low likelihood of amyloid pathology in symptomatic patients and determine whether they should proceed to further evaluation and testing that may confirm a diagnosis.

Matt Sause, CEO of Roche Diagnostics said: “We are excited to be collaborating with Lilly on such an important area of unmet medical need. Today, over 55 million people are living with dementia and this is projected to increase to nearly 140 million by 20502. Collaboration is essential to ensure these people receive a timely and accurate diagnosis. The Elecsys® Amyloid Plasma Panel has the potential to streamline a person’s journey to diagnosis and, therefore, access to future treatment options.”

Mark Mintun, Lilly group vice president – Neuroscience R&D and president, Avid Radiopharmaceuticals said: “We are pleased to be joining Roche to support the development of yet another potential diagnostic tool. We look forward to the robust data and continued collaboration across the field that will be critical to accelerate the ecosystem to aid in a timely and accurate diagnosis of Alzheimer’s.”

References

1 Life Expectancy Following Diagnosis Of Alzheimer’s Disease Depends On Age At Diagnosis, Johns Hopkins Bloomberg School of Public Health, 18 Nov. 2002, https://publichealth.jhu.edu/2002/alzheimer-age

2 World Health Organization. Dementia. https://www.who.int/news-room/fact-sheets/detail/dementia

- Advertisement -
Emma Cooper
Emma Cooper
Emma is Content Manager at Pf Media.

MORE FROM AUTHOR

- Advertisement -

LATEST POSTS

Subscribe

Sign up to receive our digital newsletter, for all the essential headlines, Jobs of the Week and thought-provoking features.

Claim my free subscription